M.A. Dooley

1.3k total citations
18 papers, 735 citations indexed

About

M.A. Dooley is a scholar working on Rheumatology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M.A. Dooley has authored 18 papers receiving a total of 735 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 4 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M.A. Dooley's work include Systemic Lupus Erythematosus Research (10 papers), Liver Diseases and Immunity (3 papers) and Hormonal and reproductive studies (2 papers). M.A. Dooley is often cited by papers focused on Systemic Lupus Erythematosus Research (10 papers), Liver Diseases and Immunity (3 papers) and Hormonal and reproductive studies (2 papers). M.A. Dooley collaborates with scholars based in United States, United Kingdom and Canada. M.A. Dooley's co-authors include Ronald J. Falk, J. Charles Jennette, Susan L. Hogan, Aziz Karim, Jeremy D. Hribar, Edward L. Treadwell, Glinda S. Cooper, Gary S. Gilkeson, E. William St. Clair and Shannon S. Currey and has published in prestigious journals such as Kidney International, Annals of the Rheumatic Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

M.A. Dooley

18 papers receiving 696 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.A. Dooley United States	10	371	214	181	101	100	18	735
Robert B. Huizinga United States	12	461 1.2×	245 1.1×	210 1.2×	144 1.4×	39 0.4×	33	709
Grace S. Park United States	19	860 2.3×	409 1.9×	82 0.5×	38 0.4×	28 0.3×	31	1.4k
A. Alonso-Ruiz Spain	10	439 1.2×	175 0.8×	275 1.5×	36 0.4×	26 0.3×	16	810
O. Mutru Finland	12	544 1.5×	99 0.5×	34 0.2×	72 0.7×	43 0.4×	14	827
Gema Fernández‐Juárez Spain	19	148 0.4×	173 0.8×	591 3.3×	22 0.2×	48 0.5×	80	1.1k
Kriengsak Vareesangthip Thailand	15	98 0.3×	32 0.1×	239 1.3×	144 1.4×	82 0.8×	42	740
Deva Situnayake United Kingdom	13	575 1.5×	155 0.7×	22 0.1×	47 0.5×	38 0.4×	24	783
Sheila Moriber Katz United States	17	131 0.4×	68 0.3×	184 1.0×	16 0.2×	83 0.8×	48	1.1k
Richard D. Wagoner United States	15	160 0.4×	64 0.3×	505 2.8×	27 0.3×	31 0.3×	19	976
Stephanie Keeling Canada	16	784 2.1×	457 2.1×	27 0.1×	38 0.4×	47 0.5×	34	1.2k

Countries citing papers authored by M.A. Dooley

Since Specialization

Citations

This map shows the geographic impact of M.A. Dooley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.A. Dooley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.A. Dooley more than expected).

Fields of papers citing papers by M.A. Dooley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.A. Dooley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.A. Dooley. The network helps show where M.A. Dooley may publish in the future.

Co-authorship network of co-authors of M.A. Dooley

This figure shows the co-authorship network connecting the top 25 collaborators of M.A. Dooley. A scholar is included among the top collaborators of M.A. Dooley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.A. Dooley. M.A. Dooley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Furie, Richard, M.A. Dooley, David Wofsy, et al.. (2018). OP0253 A phase iii randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class iii or iv lupus nephritis. Annals of the Rheumatic Diseases. 77. 176–177. 9 indexed citations

Fragoso-Loyo, Hilda & M.A. Dooley. (2014). OP0045 Efficacy of the Euro-Lupus Nephritis Regimen Combined with Abatacept VS Placebo in A North American Lupus Nephritis Population. Annals of the Rheumatic Diseases. 73. 77–78. 3 indexed citations

Jolly, Meenakshi, Mark Kosinski, Cindy Garris, et al.. (2011). PSY35 VALIDATION OF THE LUPUS IMPACT TRACKER. Value in Health. 14(3). A65–A65. 2 indexed citations

Jolly, Meenakshi, Mark Kosinski, Cindy Garris, et al.. (2011). PSY36 DEVELOPMENT OF THE LUPUS IMPACT TRACKER: A TOOL FOR PATIENTS AND PHYSICIANS TO ASSESS AND MONITOR THE IMPACT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Value in Health. 14(3). A65–A66. 3 indexed citations

El-Masry, Sahar A., M. Braithwaite, David Clark, et al.. (2010). Adherence behaviour of adult cystic fibrosis (CF) patients to prescribed azithromycin. Journal of Cystic Fibrosis. 9. S24–S24. 3 indexed citations

Bernatsky, Sasha, Rosalind Ramsey‐Goldman, David Isenberg, et al.. (2007). Hodgkin's lymphoma in systemic lupus erythematosus. Lara D. Veeken. 46(5). 830–832. 43 indexed citations

Alcorta, David A., Dwight Barnes, M.A. Dooley, et al.. (2007). Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney International. 72(7). 853–864. 44 indexed citations

Dooley, M.A.. (2006). Mycophenylate mofetil: what role in the treatment of lupus?. Lupus. 15(3). 179–182. 7 indexed citations

Parks, Christine G., Lori L. Hudson, Glinda S. Cooper, et al.. (2004). CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States. Lupus. 13(10). 784–791. 42 indexed citations

10.

Cooper, Glinda S., M.A. Dooley, Edward L. Treadwell, E. William St. Clair, & Gary S. Gilkeson. (2001). Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus.. PubMed. 28(12). 2653–6. 41 indexed citations

11.

Blalock, Susan J., Shannon S. Currey, Robert F. DeVellis, et al.. (2000). Effects of Educational Materials concerning Osteoporosis on Women's Knowledge, Beliefs, and Behavior. American Journal of Health Promotion. 14(3). 161–169. 80 indexed citations

12.

Dooley, M.A. & Ronald J. Falk. (1998). Immunosuppressive therapy of lupus nephritis. Lupus. 7(9). 630–634. 24 indexed citations

13.

Dooley, M.A., et al.. (1997). Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Kidney International. 51(4). 1188–1195. 270 indexed citations

14.

Dooley, M.A., et al.. (1991). Discrimination of antineutrophil antibodies from antinuclear antibodies using immunofluorescence on neutrophils and HL60 cells.. PubMed. 18(4). 575–9. 7 indexed citations

15.

Savvas, M., John Studd, I. Fogelman, et al.. (1988). Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women.. BMJ. 297(6644). 331–333. 61 indexed citations

16.

Steel, Linda K., et al.. (1986). Urinary Excretion of Cyclic Nucleotides, Creatinine Prostaglandin E ₂ and Thromboxane B ₂ from Mice Exposed to Whole-body Irradiation from an Enhanced Neutron Field. International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine. 50(4). 695–715. 5 indexed citations

17.

Karim, Aziz, et al.. (1976). Spironolactone. I. Disposition and metabolism. Clinical Pharmacology & Therapeutics. 19(2). 158–169. 66 indexed citations

18.

Karim, Aziz, et al.. (1976). Spironolactone. III. Canrenone—maximum and minimum steady‐state plasma levels. Clinical Pharmacology & Therapeutics. 19(2). 177–182. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact